新しい酵素法によるポリアミン測定について 第3報: 尿路性器癌患者における尿中ポリアミン分別定量

Abstract

1)健常人20例のDiamineの平均は16.6±5.8 μmoles/g.Cr., Spermidineのそれは4.7±2.0, Spermineのそれは0.99±0.51 μmoles/g.Cr.であった.M+3SDよりも高値に陽性を設置した場合, 上記3ポリアミンの陽性値はそれぞれ40, 15及び3 μmoles/g.Cr.であった.2)泌尿器科良性疾患25例では概していづれのポリアミンも陰性であったが, 前立腺肥大症ではDiamine, Spermidineが18例中1例に陽性を呈した.3)尿路性器癌の早期症例において30%の陽性率を超えたのは腎細胞癌におけるDiamineの43%と前立腺癌におけるSpermidineの40%であった.4) 3者のうちいずれか1つが陽性を示す場合の陽性率は腎細胞癌84%, 腎盂尿管腫瘍50%, 膀胱腫瘍50%, 前立腺癌41%であり, 早期症例に限っても腎細胞癌40%と比較的高い陽性率が得られ, 分別定量の有用性が示唆された

A new enzymatic method for isolation and determination of urinary polyamines was presented and basically studied in previous report 1 and 2 in comparison with existing techniques. Using the new method, urinary polyamines were isolated and determined in 56 patients with genitourinary cancer. Urinary polyamines were also determined in 63 controls consisting of 20 normal subjects, 25 patients with benign urological disease and 18 patients with BPH. The mean concentrations of Diamine, Spermidine, Spermine in 20 normal subjects were 16.6 +/- 5.8 mumoles/g Cr, 4.7 +/- 2.0 mumoles/g Cr and 0.99 +/- 0.51 mumoles/g Cr respectively. To emphasize the specificity to cancer, the level of positiveness was modified to a higher value than M+3SD. The positive values thus calculated were 40 mumoles/g Cr for Diamine, 15 mumoles/g Cr for Spermidine and 3 mumoles/g Cr for Spermine. The positive ratios of Diamine in patients with early cancer were 43% in renal cell cancer, 20% in pelvic and ureter cancer, 0% in bladder cancer and 20% in prostatic cancer. Those of Spermidine were 29% in renal cell cancer, 0% in pelvic and ureter cancer, 20% in bladder cancer and 40% in prostatic cancer. Those of Spermine were 29% in renal cell cancer, 20% in pelvic and ureter cancer, 20% in bladder cancer and 0% in prostatic cancer. In early diagnoses, Diamine indicated high positive ratios to renal cell cancer and Spermidine to prostatic cancer. Relatively high positive ratios were demonstrated, when any one of the isolated polyamines was found positive: namely, 57% in renal cell cancer, 20% in pelvic and ureter cancer, 30% in bladder cancer and 40% in prostatic cancer.(ABSTRACT TRUNCATED AT 250 WORDS)